Dec 30, 2025 • Finviz
BULLISH
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
Beam Therapeutics Inc. (BEAM) released updated safety and effectiveness data from its BEACON Phase 1/2 clinical trial for ristoglogene autogetemcel, an investigational gene-editing cell therapy for sickle cell disease. The data, presented at the 67th Annual Meeting of the American Society of Hematology, showed positive results in 31 treated adults and adolescents, including a significant decline in hemoglobin S, anemia remission, and fetal hemoglobin induction. An analyst from Evercore ISI also covered Beam Therapeutics, mentioning BEAM-302's potential for alpha-1 antitrypsin insufficiency.
Dec 30, 2025 • Insider Monkey
BULLISH
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
Beam Therapeutics Inc. (NASDAQ: BEAM) announced updated safety and effectiveness data from its BEACON Phase 1/2 clinical trial for ristoglogene autogetemcel, an investigational base editing cell therapy for sickle cell disease. The data, presented at the 67th Annual Meeting and Exposition of the American Society of Hematology, showed a decline in hemoglobin S, remission of anemia, and rapid engraftment in 31 treated patients. Separately, Evercore ISI reiterated an Outperform rating and $35 price target for BEAM, highlighting BEAM-302 as a potential treatment for alpha-1 antitrypsin insufficiency.
Dec 30, 2025 • Stock Traders Daily
NEUTRAL
(BEAM) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting a neutral mid and long-term outlook despite strong near-term sentiment. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report also emphasizes an exceptional risk-reward short setup.
Dec 25, 2025 • Simply Wall Street
BULLISH
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy
Beam Therapeutics saw a 9.9% stock increase following promising BEACON trial data for its risto-cel therapy, which proposes an innovative treatment for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio reaffirmed a positive view, noting Beam's strong manufacturing process and the FDA's RMAT designation for BEAM 101, which could streamline regulatory processes. While the data strengthens the clinical profile for sickle cell disease as a central value driver, the company still faces risks related to safety and funding.
Dec 25, 2025 • Simply Wall Street
BULLISH
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy
Beam Therapeutics (BEAM) stock surged 9.9% following encouraging BEACON trial data for risto-cel, a potential sickle cell disease treatment. H.C. Wainwright analyst Patrick Trucchio reaffirmed a positive view, highlighting the therapy's innovative potential and Beam's differentiated manufacturing process. This data, coupled with an FDA RMAT designation, strengthens Beam's investment narrative around sickle cell disease, though safety and conditioning risks still exist.
Dec 23, 2025 • Investor's Business Daily
BULLISH
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark
Beam Therapeutics (BEAM) achieved a significant technical milestone as its Relative Strength (RS) Rating climbed to 84, entering the 80-plus percentile. This improvement from 80 the previous day indicates strong price action compared to other stocks. IBD's unique rating system assesses price performance on a scale of 1 to 99.